Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-Line Chemotherapy

被引：0
|
作者：
Welin, S.
Sorby, H.
Sebjornsen, S.
Knappskog, S.
Busch, C.
Oberg, K.
机构：
来源：
NEUROENDOCRINOLOGY | 2011年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
    Leonardo Gomes da Fonseca
    Guilherme Nader Marta
    Maria Ignez Freitas Melro Braghiroli
    Aline Lopes Chagas
    Flair Jose Carrilho
    Paulo Marcelo Hoff
    Jorge Sabbaga
    BMC Cancer, 18
  • [22] First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
    Bongiovanni, Alberto
    Riva, Nada
    Ricci, Marianna
    Liverani, Chiara
    La Manna, Federico
    De Vita, Alessandro
    Foca, Flavia
    Mercatali, Laura
    Severi, Stefano
    Amadori, Dino
    Ibrahim, Toni
    ONCOTARGETS AND THERAPY, 2015, 8 : 3613 - 3619
  • [23] Effect of bevacizumab in first-line chemotherapy on progression-free survival in advanced ovarian clear cell carcinoma.
    Tate, Shinichi
    Nishikimi, Kyoko
    Matsuoka, Ayumu
    Shozu, Makio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Non-small-cell lung cancer progression after first-line chemotherapy.
    Lara Jr. P.N.
    Lau D.H.
    Gandara D.R.
    Current Treatment Options in Oncology, 2002, 3 (1) : 53 - 58
  • [25] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
    Shun Yamamoto
    Kengo Nagashima
    Takeshi Kawakami
    Seiichiro Mitani
    Masato Komoda
    Yasushi Tsuji
    Naoki Izawa
    Kentaro Kawakami
    Yoshiyuki Yamamoto
    Akitaka Makiyama
    Kentaro Yamazaki
    Toshiki Masuishi
    Taito Esaki
    Takako Eguchi Nakajima
    Hiroyuki Okuda
    Toshikazu Moriwaki
    Narikazu Boku
    BMC Cancer, 21
  • [26] Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
    Yamamoto, Shun
    Nagashima, Kengo
    Kawakami, Takeshi
    Mitani, Seiichiro
    Komoda, Masato
    Tsuji, Yasushi
    Izawa, Naoki
    Kawakami, Kentaro
    Yamamoto, Yoshiyuki
    Makiyama, Akitaka
    Yamazaki, Kentaro
    Masuishi, Toshiki
    Esaki, Taito
    Nakajima, Takako Eguchi
    Okuda, Hiroyuki
    Moriwaki, Toshikazu
    Boku, Narikazu
    BMC CANCER, 2021, 21 (01)
  • [27] The Effect of Age on First-line Chemotherapy for Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma
    Larbi, E.
    Madhuri, K.
    Essapen, S.
    Butler-Manuel, S.
    Tailor, A.
    Michael, A.
    CLINICAL ONCOLOGY, 2013, 25 (01) : 75 - 75
  • [28] First-line chemotherapy with temozolomide in recurrent/progressive oligodendroglial tumors:: A phase 2 study
    Rudà, R
    Costanza, A
    Laguzzi, E
    Trevisan, E
    Nobile, M
    Soffietti, R
    NEURO-ONCOLOGY, 2005, 7 (03) : 316 - 316
  • [29] A phase II study with temozolomide as first-line chemotherapy in recurrent/progressive oligodendroglial tumor
    Trevisan, E.
    Laguzzi, E.
    Rudà, R.
    Cassoni, P.
    Guarneri, D.
    Soffietti, R.
    NEURO-ONCOLOGY, 2006, 8 (04) : 353 - 353
  • [30] Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy
    Pierga, JY
    Asselain, B
    Jouve, M
    Diéras, V
    Carton, M
    Laurence, V
    Girre, V
    Beuzeboc, P
    Palangié, T
    Dorval, T
    Pouillart, P
    CANCER, 2001, 91 (06) : 1079 - 1089
12345